Cancer Clinical Trial -Sirnaomics-SRN-705-005

Status:

Open

ClinicalTrials.gov:

NCT04676633

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 Injected IT in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Drug

STP705

Phase

Phase I

Condition

Cholangiocarcinoma, Heptocellular, Solid Tumors With Liver Metastases

Keywords

TGF-Beta Inhibitor